<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03690362</url>
  </required_header>
  <id_info>
    <org_study_id>VNRX-5133-104</org_study_id>
    <secondary_id>272201300019C-12-0-3</secondary_id>
    <secondary_id>17-0103</secondary_id>
    <nct_id>NCT03690362</nct_id>
  </id_info>
  <brief_title>VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment</brief_title>
  <official_title>A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VenatoRx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>VenatoRx Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label, PK and safety study of VNRX-5133 and VNRX-5022 when
      co-administered in male and female subjects with varying levels of renal impairment and
      healthy normal controls.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 6, 2018</start_date>
  <completion_date type="Actual">November 21, 2018</completion_date>
  <primary_completion_date type="Actual">November 21, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study will enroll approximately 32 subjects assigned to treatment groups based on renal function.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>72 hours</time_frame>
    <description>To assess the pharmacokinetics of VNRX-5133 and VNRX-5022 in combination by assessment of Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>72 hours</time_frame>
    <description>To assess the pharmacokinetics of VNRX-5133 and VNRX-5022 in combination by assessment of AUC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of VNRX-5133 and VNRX-5022 measured as number of subjects with adverse events.</measure>
    <time_frame>8 Days</time_frame>
    <description>Number of Subjects with AEs (Assessed via patient report, physical exam, ECGs, vital signs, laboratory investigations, and use of concomitant medications for the treatment of AEs)</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Group 1 - Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy control subjects will be matched by gender, weight, and age to subjects with renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Mild Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 - Moderate Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate Renal Impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 - Severe Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe Renal Impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5 - ESRD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>End Stage Renal Disease undergoing chronic intermittent hemodialysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VNRX-5133 and VNRX-5022</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>Group 1 - Control</arm_group_label>
    <arm_group_label>Group 2 - Mild Renal Impairment</arm_group_label>
    <arm_group_label>Group 3 - Moderate Renal Impairment</arm_group_label>
    <arm_group_label>Group 4 - Severe Renal Impairment</arm_group_label>
    <arm_group_label>Group 5 - ESRD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI: 18.5-40.0 kg/m2 with a minimum weight of 45 kg

          -  Able and willing to abstain from alcohol from 48 h before admission until the
             follow-up visit

          -  Suitable veins for cannulation/multiple venipunctures, as assessed by the Investigator
             at Screening

          -  Males who are not surgically sterilized and females of childbearing potential must
             agree to use highly effective methods of contraception during the study and for 90
             days after study drug administration.

          -  Laboratory values meeting defined entry criteria

        Subjects with normal renal function (Group 1) must also meet the following criteria:

          -  Match to one or more subjects with renal impairment by gender, age, and weight

        Subjects with renal impairment (Groups 2-5) must also meet the following criteria:

          -  Stable, pre-existing renal impairment.

        Exclusion Criteria:

          -  Employee of the study site, Contract Research Organization (CRO) or the IND Sponsor

          -  Female who is pregnant, lactating, or planning to attempt to become pregnant during
             the study or within 90 days after study drug administration

          -  Male with a female partner who is pregnant or lactating during the study, or planning
             to attempt to become pregnant during the study or within 90 days after study drug
             administration

          -  Use of any investigational drug or device within 30 days before study drug
             administration (90 days for an injectable biological agent)

          -  The subject has a congenital or acquired immunodeficiency syndrome

          -  Screening or Day -1, clinically significant abnormal ECG values

          -  Active malignancy; exceptions are permitted for carcinoma in situ of the prostate or
             the skin (basal cell or squamous cell) are permitted

          -  History of drug allergy of a severity that required urgent medical treatment, such as
             treatment with epinephrine in an Emergency Department

          -  Known immediate hypersensitivity reaction following administration of a cephalosporin,
             penicillin, or other β-lactam antibacterial drug

          -  History of donation of more than 450 mL of blood within 60 days before dosing in the
             site or planned donation before 30 days has elapsed since ingestion of study drug

          -  Plasma or platelet donation within 7 days of dosing and throughout the study

          -  Consumes more than 7 drinks/week for women or 14 drinks/week for men (1 drink = 5
             ounces of wine, 12 ounces of beer, or 1.5 ounces of hard liquor) or has a significant
             history of alcohol abuse or drug/chemical abuse within the last 1 year

          -  Oral temperature &gt;38.5˚C or acute illness on Day -1

          -  Previous participation in a study of VNRX-5133

          -  Excluded concomitant medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Orlando Cliniical Research Associates</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>February 7, 2019</last_update_submitted>
  <last_update_submitted_qc>February 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

